Bayer AG Non-GAAP EPS of ?0.62, revenue of ?11.44B; introduces FY26 outlook
Source: SeekingAlpha
2026-03-04 03:23:42 ET
More on Bayer
- Bayer Aktiengesellschaft (BAYRY) Discusses Roundup Class Settlement Agreement and Implications for U.S. Glyphosate Litigation Transcript
- Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention - Slideshow
- Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention Transcript
- Bayer releases promising early-stage data on prostate cancer therapy
- Bayer says Xofigo/Xtandi combo shows overall survival benefit in prostate cancer
Read the full article on Seeking Alpha
For further details see:
Bayer AG Non-GAAP EPS of ?0.62, revenue of ?11.44B; introduces FY26 outlook
Bayer AG Registered Shares
NASDAQ: BAYZF
BAYZF Trading
0.0% G/L:
$44.17 Last:
187 Volume:
$44.17 Open:
BAYZF Latest News
March 04, 2026 08:00:00 am
New FDA 510(k) Clearance Expands Bayer's MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
February 27, 2026 12:43:00 pm
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
